Advances in Crohn's Disease: A Comprehensive Review of Pathophysiology, Diagnosis, and Emerging Therapeutics

Crohn's disease (CD) is a chronic inflammatory condition of the bowel with a rising global incidence. Its complex etiology involves genetic susceptibility, environmental factors, and alterations in the gut microbiota, leading to dysregulated immune responses. Prompt diagnosis and personalized treatment are essential to prevent disease flares and complications. This review provides a comprehensive overview of CD, including its epidemiology, pathophysiology, diagnosis, management, treatment goals, and prospects. Treatment goals in CD have evolved beyond symptomatic control to achieving mucosal healing to prevent disease related complications. Advances in biologic therapies including the use of anti-TNF agents, vedolizumab, and ustekinumab in CD have improved outcomes, but challenges such as immunogenicity and accessibility remain. A 'treat-to-target' approach based on biomarkers such as C-reactive protein and fecal calprotectin allows for objective disease monitoring and adjustment of treatment as needed to achieve these targets. Promising new drug classes including Janus kinase inhibitors and anti-interleukin-23 antibodies are emerging as potential therapies. Personalized medicine is evolving as a vital approach to tailor treatment based on individual genomic, clinical, and environmental factors. Future research to refine CD management should focus on predictive biomarkers, treatment algorithms, and head-to-head trials. Overall to improve outcomes and quality of life for those living with CD, management requires a multifaceted approach that considers disease severity, individualized patient characteristics, and the evolving therapeutic landscape.